Drug Discovery World

AUGUST 29, 2024

HTS compatible cellular assays Robert G Lowery PhD, President & CEO at BellBrook Labs, comments: “AI and virtual screening are increasing the diversity of targets in drug discovery, but developing virtual hits still requires wet biology, using technologies developed over the last 25 years.

Small Molecule 147

Small Molecule Drugs Protein Expression Assay Development 147

Sygnature Discovery

JUNE 17, 2024

Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities. Sygnature Discovery’s Biophysical Assay Development Capabilities: 1.

Biophysical Assays 52

Biophysical Assays Screening Hits Fragment Screening Assay Development 52

Elrig

APRIL 29, 2024

Harini joined Serna Bio in early 2021 and has been an integral part of the multidisciplinary teamworking on target ID platform development to drug discovery. She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures.

Bioinformatics 59

Bioinformatics Molecular Biology Drugs Cell Based Assays 59